Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00705549
Other study ID # CT/07.23
Secondary ID
Status Terminated
Phase Phase 2
First received June 25, 2008
Last updated February 12, 2013
Start date February 2008
Est. completion date September 2011

Study information

Verified date February 2013
Source Hellenic Oncology Research Group
Contact n/a
Is FDA regulated No
Health authority Greece: National Organization of Medicines
Study type Interventional

Clinical Trial Summary

This is a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC using chemotherapy regimens which will be defined according to the pharmacogenomic profile (tumoral expression of ERCC1, BRCA1 and RRM1) of the tumor cells.


Description:

Advanced stage NSCLC is essentially a fatal disease and treatment is mainly palliative. Systemic cisplatin-based chemotherapy remains the mainstream for the treatment of advanced non-small cell lung cancer (NSCLC) since it improves survival, symptom control and quality of life compared to best supportive care.

The selection of appropriate treatment for individual patients remains a challenge in clinical oncology, particularly in the advanced disease. Several lines of evidence indicate that polymorphisms, gene transcripts and gene mutations can play a predictive role and can be used to tailor chemotherapy in different subgroups of cancer patients. There are evidence lead us to use the expression levels of ERCC1 by the tumor as a molecular marker for customized chemotherapy. Another gene, the BRCA1 has a crucial role in DNA repair, since it is implicated in transcription-coupled nucleotide excision repair (TC-NER), leading to radio- and chemo-resistance. RRM1,localized in 11p15.5,also acts as a putative tumor suppressor gene. RRM1 overexpression was related to gemcitabine resistance in human oropharyngeal epidermoid carcinoma KB cells as well as in patients with NSCLC. For those reason we decided to conduct a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC using chemotherapy regimens which will be defined according to the pharmacogenomic profile (tumoral expression of ERCC1, BRCA1 and RRM1) of the tumor cells.


Recruitment information / eligibility

Status Terminated
Enrollment 88
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with histologically proven Stage IV and Stage III (with malignant pleural or pericardial effusion) squamous or adenocarcinoma carcinomas of the lung

- Adequate Formalin Fixed Paraffin Embedded tumor sample provided for molecular analysis

- No previous anticancer treatment for metastatic/advanced disease. Patients who received prior adjuvant chemotherapy are eligible if they have remained free of disease for at least 6 months after the completion of adjuvant therapy.

- Age above 18 years

- Performance status (ECOG) 0-2

- Life expectancy >= 3 months

- Effective contraception for both male and female subjects if the risk of conception exists

- Adequate hematologic parameters (absolute neutrophil count >= 1.5x109/L and platelets >= 100x109/L), creatinine (GFR>= 60ml/min) and total bilirubin < 1.5 times the upper limit of normal; aspartate and alanine aminotransferase < 2,5 times the upper limit of normal

- All patients will have to sign written informed consent in order to participate in the study

Exclusion Criteria:

- Patients with non-squamous tumors who have no contradiction for administration of bevacizumab

- Active infection or malnutrition (loss of more than 20% of the body weight)

- Known hypersensitivity reaction to any of the component of the treatment

- Concurrent or previous chronic systemic immune therapy

- Pregnancy (absence to be confirmed by ß-HCG test) or lactation period

- Known alcohol/drug abuse

- Legal incapacity or limited legal capacity

- Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent

- A second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma

- Previous radiotherapy to the target lesions. Patients treated with palliative radiotherapy had to have measurable metastatic disease outside the irradiation fields

- Patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of uncontrolled arrhythmia

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Gemcitabine
Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
Cisplatin
Cisplatin I.V at the dose of 75mg/m2 on Day 1
Docetaxel
Docetaxel I.V at the dose of 75mg/m2 on Day 1
Cisplatin
Cisplatin I.V at the dose of 80mg/m2 on Day 1
Vinorelbine
Vinorelbine per os 50mg every Monday, Wednesday and Friday
Pemetrexate
Pemetrexate I.V 500mg/m2 on Day 1

Locations

Country Name City State
Greece University General Hospital of Alexandroupolis, Dept. of Medical Oncology Alexandroupolis
Greece "Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine Athens
Greece 401 Military Hospital, Medical Oncology Unit Athens
Greece Air Forces Military Hospital, Dep of Medical Oncology Athens
Greece IASO" General Hospital of Athens, 1st Dep of Medical Oncology Athens
Greece Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases Athens
Greece Sotiria" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases Athens
Greece "Metaxa's" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology Piraeus
Greece "Theagenion" Anticancer Hospital of Thessaloniki Thessaloniki

Sponsors (2)

Lead Sponsor Collaborator
Hellenic Oncology Research Group University Hospital of Crete

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) based on the pharmacogenomic profile of the ERCC1, RRM1 and BRCA1 expression Objective responses confirmed by CT or MRI No
Secondary Determine the incidence of the different pharmacogenomic profiles as defined by the combined expression of ERCC1, RRM1 and BCRA1 Comparison of molecular determinants for response in the primary tumor and peripheral blood (ERCC1 polymorphism ,TXR1 and TSP1 mRNA expression by Q-RT-PCR, Molecular markers related to responsiveness to Alimta ) No
Secondary Time to Tumor Progression 1 year No
Secondary Overall Survival 1 year No
Secondary Toxicity Toxicity assessment on each chemotherapy cycles Yes
See also
  Status Clinical Trial Phase
Terminated NCT02495233 - A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) Phase 1/Phase 2
Withdrawn NCT02672358 - Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC Phase 2
Recruiting NCT05815472 - Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT) N/A
Not yet recruiting NCT05900219 - Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study Phase 2
Not yet recruiting NCT04560244 - A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment Phase 2
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT01924416 - Lung Cancer Information Study (LCIS-R01) N/A
Completed NCT01136083 - Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients N/A
Completed NCT00831454 - Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection N/A
Completed NCT00363766 - Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Completed NCT00913705 - Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer Phase 3
Completed NCT01383135 - Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 Early Phase 1
Completed NCT01124864 - A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. Phase 2
Completed NCT00049998 - Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer Phase 3
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT03320044 - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting NCT04895930 - Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC Phase 2
Recruiting NCT03267654 - Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance Phase 2
Recruiting NCT04401059 - Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study Phase 4
Not yet recruiting NCT02938546 - 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study Phase 3